Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study

NCT02342392 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Pterygium

Interventions

DRUG: ranibizumab

Sponsor

Universiti Sains Malaysia